Striking regression of advanced prostatic carcinoma induced by cyproterone acetate (Androcur). A case report

An 80-year-old man with advanced adenocarcinoma of the prostate received cyproterone acetate, 200 mg orally per day as sole treatment. Striking regression of the tumour was demonstrated by ultrasonograms and excretory urograms. Serum concentrations of acid phosphatases, gonadotrophins, and testosterone decreased significantly. No significant cardiovascular side effects occurred.